semaglutide Week 1-12 Bundle - An Overview
The trial realized both equally its Key endpoints, with semaglutide 2.four mg demonstrating statistically significant and exceptional advancements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH in comparison to placebo.oneConnect with your health c